Sign Out
Animal reproduction studies have not shown evidence of harmful effects on the fetus. There are, however, no studies in pregnant women. Treatment with Genotropin should be interrupted if pregnancy occurs.
During normal pregnancy, the levels of pituitary growth hormone markedly fall after Week 20 of gestation, being replaced almost entirely by placental growth hormone by Week 30. Therefore, it is unlikely that continued replacement therapy with somatropin would be necessary in growth hormone deficient women during the third trimester of pregnancy.
It is not known if somatropin is excreted into breast milk, but absorption of intact protein from the gastrointestinal tract of the infant is extremely unlikely.
